Brief: Apollomics Presents Interim Data from Two Ongoing Phase 2 Clinical Trials with Vebreltinib in NSCLC Patients with MetExon14 Skipping Mutation
04/12/2023 12:51
Dec 4 (Reuters) - Apollomics Inc APLM.O :
* APOLLOMICS PRESENTS INTERIM DATA FROM TWO ONGOING PHASE 2
CLINICAL TRIALS WITH VEBRELTINIB IN NSCLC PATIENTS WITH
METEXON14 SKIPPING MUTATION
Source text for Eikon: ID:nGNXt1vyQ
Further company coverage: APLM.O
((Reuters.Briefs@thomsonreuters.com;))